Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab and Pembrolizumab in Solid Tumors (CIRIFOUR)
NCT04452214Phase 1Completed
- Sponsor
- Cantargia AB
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nadunolimab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma (UC) and 1 more (2 arms), sponsored by Cantargia AB. Primary endpoints: Treatment-Emergent Adverse Events at 6 months, Dose-Limiting Toxicities at 28 days and 1 more. Started Sep 2020; status: completed.
02
Drugs
nadunolimab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04452214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452214.